October 2025 Manuscript "Biliverdin reductase B as a new target in breast cancer" is published in Breast Cancer Research

​

September 2025 BCT receives NCI SBIR Fast Track Award "Development of Second Generation BLVRB Inhibitors for Treating Chemotherapy Induced Thrombocytopenia"

 

April 2025 Manuscript "Small molecule BLVRB redox inhibitor promotes megakaryocytopoiesis and stress thrombopoiesis in vivo" is published by Nature Communications

​

March 2025 PCT Patent WO2025064210A1 is published

​ 

August 2024 Blood Cell Technologies becomes a resident of JLABS@NYC

​

September 2024 Composition of matter patent finalized; International PCT filed to protect BLVRB inhibitors

 

September 2023 Composition of matter provisional patent filed to protect first-in-class BLVRB inhibitors with finalization anticipated September 2024

​

September 2023 BCT Receives SBIR Phase I Award “Development of a new class of BLVRB-targeted redox therapeutics in breast cancer”

​

October 2022 BCT receives NIH Technical and Business Assistance (TABA) funding to assist with Intellectual property protections

 

September 2021 BCT Receives SBIR Phase II $2.07M Award “Optimization of biliverdin IXβ reductase redox inhibitors as novel reagents for enhancing platelet production”

 

June 2020 BCT Receives SBIR Phase I Award “Detection of fetal platelets in maternal blood using platelet RNA biomarkers”

 

September 2017 BCT Receives SBIR Phase I Award “HLS Detection of RNA biomarkers in individual platelets”

 

July 2015 BCT receives SBIR Phase I Award “Development of a biliverdin IX Beta reductase redox inhibitor for enhanced platelet production”

July 2015 Blood Cell Technologies founded as a limited liability corporation (LLC)